Aim Pseudomyxoma peritonei (PMP) is a rare neoplasm of the appendix, which if untreated disseminates throughout the abdominal cavity and generates considerable morbidity. Since 2002 in the UK, patients with PMP have been managed via two nationally commissioned centres. We evaluated referrals and treatment pathways over time at the Manchester centre.
Introduction
Pseudomyxoma peritonei (PMP) is a rare epithelial neoplasm, arising in most cases from a lesion of the appendix known as a low grade appendiceal mucinous neoplasm (LAMN) and characterized by the progressive accumulation of mucinous ascites [1] . The incidence of PMP in western populations is 1.8 per million population, translating to approximately 120 new cases per year in the UK [2] . Historically, treatment for PMP involved symptomatic relief only, with serial drainage of mucinous ascites or debulking and little prospect of long-term survival. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) as pioneered by Sugarbaker is now accepted as the standard of care for PMP [3] . Overall 5-, 10-and 15-year survival in patients treated by this modality is 75%, 63% and 59%, respectively [4] .
Since 2002, services for PMP in the UK have been commissioned centrally via specialist centres in Manchester and Basingstoke. This approach ensures that centres receive the case volume required to develop expertise in diagnosis and treatment and establish robust pathways for patient referral in this relatively rare disease. Commissioning arrangements include monitoring of the service and quality assurance within agreed specifications [5] . Previous studies reported experiences from the individual UK treatment centres [6] [7] [8] : the steep learning curve associated with CRS and HIPEC [9] and long-term survival outcomes [4] . However, limitations of existing evidence have been the inclusion of heterogeneous series of histopathological types [8] and incomplete or absent disease staging [4, 8] .
This study aims to evaluate changes in the stage of disease at presentation over a 13-year period in a single centre, assessed prospectively by intra-operative staging with the Peritoneal Cancer Index (PCI) and by the proportion of complete cytoreductions determined by the completeness of cytoreduction score (CC score), as a surrogate quality indicator. We describe how the clinical service has evolved to identify a clinico-pathological early stage disease state [10] and to develop novel management strategies to minimize the risk of disease progression [11] .
Method Population and pathways
Data were extracted from a custom designed prospectively maintained database. All patients referred to the service between January 2002 and December 2015 with a confirmed diagnosis of LAMN or PMP of appendiceal origin were included. Histological diagnostic criteria and classifications were in accordance with the Peritoneal Surface Oncology Group International (PSOGI) consensus classification [12] . Patients with appendiceal goblet cell tumours and with adenocarcinomas were excluded; the latter are reported elsewhere [13] .
All patients referred to the service with a suspected diagnosis of LAMN or PMP are discussed by the dedicated peritoneal tumour multidisciplinary team, comprising colorectal and hepatobiliary surgeons, clinical oncologist, radiologist, pathologist, HIPEC practitioners and specialist nurses. All cases undergo in-house pathological and radiological review. Patients with disseminated disease undergo CRS and HIPEC or, if complete CRS and HIPEC are deemed unachievable, undergo debulking surgery provided they are fit for major surgical intervention. A proportion of patients with unresectable disease were offered either systemic chemotherapy with mitomycin C and capecitabine (MCap) [14] or best supportive care.
During the evolution of the clinical service, we identified a specific group of patients with a histological diagnosis of LAMN with localized disease limited to the appendix and the immediate peri-appendiceal area, i.e. without clinical identifiable intra-abdominal dissemination. We sub-classified these cases based on clinicopathological features indicative of risk of dissemination [10] as follows: (i) LAMN I, where the lesion was limited to the subserosal appendix with no evidence of appendiceal perforation; and (ii) LAMN II, where the lesion was characterized by appendiceal perforation and/ or accompanied by mucin (with or without cells) in the appendix serosa and the peri-appendiceal tissues. The literature demonstrates that LAMN I rarely develops into disseminated disease [15] [16] [17] so these patients were offered a programme of active surveillance with interval tumour markers and CT scanning. By contrast, LAMN II is associated with risk of progression to disseminated disease [15, 17] , with rates in the literature ranging from 16% in a large Danish population based study [18] to 23% in a more recent North American cohort [19] . Patients with LAMN II are counselled and offered riskreducing CRS and HIPEC. Some, mainly elderly, patients opt for the LAMN I surveillance pathway. Since 2010, we have offered a minimal access approach for this risk-reducing cytoreductive operation [11] .
Surgical procedure
Cytoreductive surgery involves removal of the appendix and all visible disease by peritonectomy and resection of involved non-essential viscera. In addition, target organs at high chance of involvement and future relapse are resected. Liver surface disease is treated ablatively with high-power electrocautery. HIPEC with mitomycin C (35 mg/m 3 in three pulses) is administered after CRS in a semi-closed modification of the coliseum technique [13] . Details of the minimally invasive cytoreductive surgery procedure are described in an earlier publication [11] .
Surveillance
The surveillance pathway for patients with LAMN I involves a six-monthly review with serum tumour markers (serum CEA, CA19-9 and CA125) plus annual CT scans for 5 years and a CT scan at year 8.
Outcomes
Disease burden was quantified intra-operatively using the PCI which scores 13 abdominal sites from 0 (no disease) to 3 (lesions > 5.0 cm or confluence) giving a score from 0 to a maximum of 39 [20] . Operative disease clearance was quantified by the CC score, assessed intra-operatively at completion of CRS. A score of CC-0 indicates no visible evidence of peritoneal disease, CC-1 indicates residual tumour < 2.5 mm in diameter, CC-2 residual tumour between 2.5 mm and 2.5 cm in diameter and CC-3 residual tumour > 2.5 cm in diameter or confluence of tumour nodules at any site. CC0/1 is considered complete cytoreduction and CC2/3 is considered debulking [21] . Risk-reducing CRS and HIPEC are defined as CRS and HIPEC for localized disease (LAMN II and PCI < 3). Complications were recorded prospectively and classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria, the agreed classification system to be used for reporting complications relating to CRS and HIPEC [22] .
Statistical analysis
A complete case analysis approach was used. Twentyfive cases where the PCI score or CC score was not recorded were excluded from analysis. For descriptive purposes, we divided our cohort into four approximate quartiles based on the number of referred cases, as used in equivalent papers [8] . These quartiles corresponded to the four time cohorts ( We tracked the geographical residence of patients with postal codes using Tableau Software (Seattle, Washington, USA), and visually examined for changes in geographical referral variations over the four TCs.
Peritoneal Cancer Index data were modelled with time using spline regression repeated iteratively for cutoff points at each year to determine the optimal pivot, as described elsewhere [23] . Confidence intervals for proportions were calculated using the Wilson score method without continuity correction [24] . The Cochran-Armitage test [25] was used for trends in proportions. The chi-squared test was used for differences in proportions.
Overall survival probabilities (any cause of death) were estimated from time of operation using KaplanMeier life tables. Comparisons were performed using log-rank tests. All analyses were carried out using 
Results

Referral patterns
Over the 13-year period, 1047 patients with suspected PMP were referred to the Colorectal and Peritoneal Oncology Centre (Fig. 1) . The following were excluded: 205 with non-PMP pathologies and 25 with missing PCI or CC scores. The principal analysis was of the remaining 817 patients with confirmed PMP either as disseminated (N = 612) or localized (N = 205) disease.
Patients were referred mainly from the north and Midlands of England, Scotland, Northern Ireland and North Wales. Over the four TCs, the geographical distribution of referrals was similar (Fig. 2) .
The total number of referrals per year increased over the 13-year period. In particular, patients referred with localized disease significantly increased over time (P trend < 0.0001) and constituted over 25% of referrals per year since 2010 and 32% of referrals in 2015 alone (Fig. 3) .
Management pathways
Of the 612 patients with disseminated disease, 330 (40%) underwent CRS and HIPEC. For the remaining 282 patients, management was palliative drainage (N = 16), palliation (N = 128), systemic MCap chemotherapy (N = 40) and active monitoring (N = 55) (Fig. 1) . Forty-three patients declined treatment/follow-up, were transferred to an alternative centre for treatment, were lost to follow-up or died before treatment was commenced.
Of the 205 patients (23%) with localized disease (LAMN I or II), 129 (63%) were managed with active surveillance. Seventy-six (37%) patients with LAMN II underwent risk-reducing CRS and HIPEC, and since 2010 the majority of these were treated via a minimally invasive approach (Table 1) .
Disease burden
Peritoneal Cancer Index scores are plotted against year of operation for cytoreduction (CC0/CC1) and debulking (CC2/CC3) procedures (Fig. 4) . For the first quartile of cases, disease burden was high (mean PCI 31) and levelled off thereafter (15, 15, 17 ; P = 0.002). There was an absence of low (< 20) PCI values in the early study period. We tested statistically for a pivot in the data using spline models. The optimal pivot was at 2007 (P = 0.002). The spline regression for yearly mean PCI scores for years 2002-2007 declined significantly (P < 0.001), but the yearly mean score levelled off thereafter (P = 0.48).
Surgical clearance of disease
Of patients undergoing major laparotomy for disseminated disease, the proportion undergoing complete cytoreduction (CC0/1) was 66.7% (56/84) in the first TC. This increased to 77.1% (54/70) in TC2 although the increase was not statistically significant (P = 0.14). Proportions of complete cytoreduction in TC3 and TC4 were 73.6% (67/91) and 74.1% (63/85), respectively (Fig. 5) . CC0 cytoreduction was achieved in all patients undergoing risk-reducing CRS and HIPEC.
Complications
Rates of National Cancer Institute CTCAE Grades 3-5 surgical complications for all CRS and HIPEC procedures by TC were 4.3%, 9.5%, 14.5% and 12.5%. There was one 30-day mortality.
Survival
Five-and 10-year overall survival for patients undergoing CRS and HIPEC for disseminated disease (excluding risk-reducing procedures) was 77% and 66%, respectively. Incomplete cytoreduction (CC2/3) was associated with significantly worse survival compared with complete cytoreduction (CC0/1) (P < 0.0001) (Fig. 6 ).
Discussion Main findings
This paper describes the evolution of a nationally commissioned specialist service over 13 years. The number of referrals received has increased over time. The increase is likely to be driven by the establishment of robust referral pathways resulting in increased awareness of services amongst the referring community. High volumes of disease were seen in the early years of the service, illustrated by the high mean PCI score in TC1 [31], but mean PCI score stabilized at a lower level over subsequent years. This most probably represents an initial phase where patients with established advanced disease accessed the service following increased awareness of the healthcare provider. The number of patients referred with localized disease (LAMN) has increased, representing a progressively greater proportion of the total referrals year on year. This increase may be explained by an increasing awareness of the role of appendiceal precursor lesions in the development of PMP and better understanding of specialist services (e.g. through national meetings and multidisciplinary team workshops). We have described new risk stratified management pathways for patients with localized disease, which balance the potential morbidity of intervention against the risk of developing disseminated disease.
Context of other literature
The classification of PMP and its appendiceal precursor has been the subject of extensive debate in the literature, prompting the publication of an international consensus for classification and pathological reporting in 2016 [12] . The consensus document clearly differentiates between appendiceal mucinous neoplasms and appendiceal mucinous adenocarcinoma. The latter term is reserved for mucinous tumours with infiltrative invasion, associated with a more aggressive natural history, metastasizing systemically in up to 20% of cases [18] . To our knowledge, this is the only study to date to describe a homogeneous, pathologically consistent cohort of patients with PMP originating from appendiceal mucinous neoplasia excluding appendiceal adenocarcinoma.
Rates of complete cytoreduction for disseminated disease in our cohort have remained around 74% since 2007, reflecting the relatively constant yearly mean PCI score observed after the first quartile. Chua et al. reported a pooled analysis from 16 units across three continents and quotes an overall CC0/1 rate of 83% [4] . It is important to note that this analysis pooled all data without simultaneously accounting for betweencentre variance and arguably our proportion of 74% would fall within this range. Further, in our series, riskreducing procedures have been considered separately, and when these are included the CC0/1 rate is more comparable at 79%. The importance of achieving complete cytoreduction is underlined by the significant difference in survival between those undergoing CC0/1 resection and those undergoing debulking (CC2/3). Notably, there are no survivors beyond 9 years in the latter group. Combined overall survival at 5 and 10 years in our cohort (77% and 66%, respectively) is comparable to other published series, which range from 51% to 82% at 5 years [4, 6, 26, 27] and from 32% to 76% at 10 years [4, 8, 26] .
Strengths and limitations
This study has several strengths. First, data on treatments, complications, PCI and surgical and oncological outcomes were collected prospectively. Second, we present a large, mature and pathologically homogeneous dataset, with a minimum follow-up period of 3 years and minimal missing data (3%) across all fields. The only other study to report PCI score in patients undergoing CRS and HIPEC for PMP [4] cites the PCI score as missing in 35% of cases. Third, we included the management outcomes of all patients referred with PMP, including those not undergoing surgery Other studies have either excluded patients not undergoing surgery [4, [26] [27] [28] , or reported the proportion of referred patients not undergoing CRS and HIPEC but included a heterogeneous case mix of peritoneal surface malignancies including mesothelioma and colorectal peritoneal metastases and provided no further detail on the management outcomes of this group [8] .
The limitations of this study relate to the difficulties associated with describing long-term outcomes beyond survival. We describe overall survival but do not report disease-free interval or progression largely because a clear and consistent definition of progression in the context of PMP has not yet been agreed. One recent large multicentre cohort reported progression-free survival [4] in the context of disseminated disease, but did not provide an accompanying definition of progressionfree survival. An earlier single centre cohort included rise in tumour markers in its definition of progression [29] . A reproducible definition will need to specify disease criteria (new lesions and quantifying change in existing lesions) and assessment modality [13] . Such outcomes will be particularly important in the longterm follow-up of patients having risk-reducing procedures or under active surveillance for localized disease, and therefore agreeing consistent and reproducible outcome measures is a key research priority.
Future research
Earlier referral of patients with localized disease has allowed an increasing number of patients to be managed either by risk-reducing surgery or active surveillance. The long-term impact of these management pathways on survival and disease progression is being monitored over time.
High 5-and 10-year survival rates following complete cytoreduction for disseminated disease is clearly a success, but survivors are now living with morbidities following CRS and HIPEC. We have recently analysed and reported quality of life in patients undergoing CRS and HIPEC for PMP showing impaired cognitive function at 1 year post-treatment [30] . We are currently undertaking qualitative work to understand the priorities of patients in this population. In conclusion, central commissioning of specialist services has facilitated the development of robust referral pathways leading to high volume specialist centres with quality assured outcomes. These features of centralization are associated with favourable outcomes in patients with PMP [9] . Our data illustrate the change over time in disease stage at referral, demonstrating a clear trend towards referral at an earlier stage of disease, and describe new risk stratified management pathways. We speculate that in the long term these service changes will result in improved survival, reduced treatmentrelated morbidity and improved health-related quality of life, and these are areas for ongoing research.
